Trial Profile
A 12 Week, Multicenter, Pharmacokinetic and Safety Study of Human Plasma-Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Factor XIII (Primary)
- Indications Congenital disorders; Factor XIII deficiency; Haemorrhage
- Focus Pharmacokinetics
- Sponsors CSL Behring
- 25 Apr 2014 New trial record
- 25 Apr 2014 New source identified and integrated (European Clinical Trials Database; EudraCT2009-010387-41)